Purple Biotech PPBT 深 沪
等待开盘 03-26 09:30:00 美东时间
4.14
+0.175
+4.41%
华盛通- 最 高4.18
- 今 开4.10
- 成交量 1.33万股
- 最 低 3.79
- 昨 收 3.965
- 总市值 373.86万
- 52周最高 29.40
- 市盈率 静 --
- 换手率 1.48%
- 52周最低 3.65
- 委 比 -64.84%
- 总股本 90.30万
- 历史最高 13900.00
- 量 比 1.76
- 振 幅 9.84%
- 历史最低 3.79
- 每 手 1
- 风险率 9.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing
03-25 20:02
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Purple Biotech collaborates with Converge Bio to enhance its tri-specific antibody platform using AI, aiming to accelerate development and improve molecule quality for oncology targets. The partnership leverages Converge Bio's AI for faster, higher-quality drug discovery, targeting solid tumors. Purple's CAPTN-3 platform focuses on tumor-targeting antibodies engaging T and NK cells for improved efficacy and reduced toxicity. This collaboration co...
03-25 12:00
Purple Biotech regains compliance with Nasdaq
Purple Biotech (PPBT) has announced that it received confirmation from the Nasdaq that the Company had regained compliance with the minimum bid price requirement under Nasdaq rules for continued listi...
03-17 19:19
Purple Biotech Regains Compliance with Nasdaq
REHOVOT, Israel, March 17, 2026 – Purple Biotech Ltd. has regained compliance with Nasdaq's minimum bid price requirement, maintaining a $1.00 closing bid price for its ADSs for 10 consecutive business days, achieved on March 13, 2026. The Company, focused on developing next-generation immunotherapy platforms to maximize anti-cancer potency while minimizing toxicity, is advancing several candidates including IM1240, IM1305, CM24, and NT219. These...
03-17 11:00
Purple Biotech Non-GAAP EPS of $19.85
Purple Biotech press release (PPBT): Q4 Non-GAAP EPS of $19.85. Operating Loss was $23.4 million, an increase of $22.4 million, compared to $1.0 million in the same period of 2024, primarily reflectin...
03-14 03:21
Purple Biotech Q4 EPS $19.85 Beats $(3.40) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly earnings of $19.85 per share which beat the analyst consensus estimate of $(3.40) by 683.82 percent. This is a 863.46 percent increase over losses of $(2.60) per share from
03-13 21:28
Purple Biotech CEO Gil Efron to step down
Purple Biotech (PPBT) on Friday said that Gil Efron will step down from his role as CEO effective August 2026. Efron has served in senior leadership roles at Purple Biotech for the past eight years, i...
03-13 20:31
Purple Biotech Announces CEO Transition
Gil Efron, CEO of Purple Biotech Ltd., will step down as CEO effective August 2026 due to health considerations. He will continue to lead corporate development and remain on the Board of Directors. The Board will begin a formal search for a new CEO. Efron has served in senior roles for eight years, playing a key role in repositioning the company around the CAPTN-3 tri-specific antibody platform. The company is advancing its lead asset and pipelin...
03-13 12:04
Eli Lilly and Co Stock Closed Down by 3.27% on Mar 2: Facts Behind the Movement
• Eli Lilly's stock declined due to market corrections and valuation concerns. • Geopolitical events and rising oil prices triggered a broader market downturn. • Competition and potential pricing pressures impact the GLP-1 market.
03-02 21:14
Purple Biotech Announces Plan To Implement ADS Ratio Change From 1-To-200 To 1-To-2,000, Effective March 2nd
The primary purpose of the ADS Ratio Change is to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").
02-26 06:04
